Gilead Stock Today

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>GS</div>
Gilead Sciences is trading at 77.19 as of the 15th of July 2020, which is 0.67 percent increase since the beginning of the trading day. The stock's lowest day price was 75.44. Gilead Sciences has a very small chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 30 days. Equity ratings for Gilead Sciences are calculated daily based on the scoring framework. The performance scores are derived for the period starting the 16th of April 2020 and ending today, the 15th of July 2020. Click here to learn more.
Analyze Filter   Report: 4th of August 2020

   Performance
1 100 

Gilead Sciences Profile

The upcoming quarterly report is expected on the 4th of August 2020. Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 11800 people. more on Gilead Sciences
Gilead Sciences Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Gilead Sciences SEC Filings
Gilead Sciences SEC Filings
Security & Exchange Commission EDGAR ReportsView All
Legal NameGilead Sciences
Chairman and CEOJohn MartinView All
Thematic Classifications
Active investing themes Gilead Sciences currently participates. An investing theme is an unweighted collection of funds, stocks, ETFs or cryptocurrencies
showing 2 out of 3 themes  View All
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering Gilead Sciences. The Gilead consensus assessment is calculated by taking the average estimates from all of the analysts covering Gilead Sciences
Piotroski F Score
Academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Gilead Sciences financial position. Scores of 8 and 9 are usually clasified strong value stocks whereas scores of 2 or below are considered weak value stocks.
 8 - StrongDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares1.3 B1.3 B
Fairly Up
Decreasing
Slightly volatile
Weighted Average Shares Diluted1.3 B1.3 B
Sufficiently Up
Decreasing
Slightly volatile
Net Cash Flow from Operations9.9 B9.1 B
Significantly Up
Increasing
Slightly volatile
Total Assets54.6 B61.6 B
Fairly Down
Increasing
Slightly volatile
Total Liabilities34.3 B39 B
Fairly Down
Increasing
Slightly volatile
Current Assets26.3 B30.3 B
Fairly Down
Increasing
Slightly volatile
Current Liabilities9.1 B9.8 B
Significantly Down
Increasing
Slightly volatile
Total Debt22.1 B24.6 B
Moderately Down
Increasing
Slightly volatile
Return on Average Assets0.140.087
Way Up
Decreasing
Slightly volatile
Gross Margin0.880.792
Significantly Up
Increasing
Slightly volatile
Asset Turnover0.430.364
Fairly Up
Decreasing
Slightly volatile
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Gilead Sciences available fundamental, technical, and predictive indicators. Current horizon is 30 days (very short) - details
Financial Strength
Gilead Sciences financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Gilead Sciences success along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
A- ( Average Bond Rating ) Very Good
  Operating Cash Flow
Gilead Sciences (GILD) is traded on BATS Exchange in USA. It is located in 333 Lakeside Drive, Foster City, CA 94404, United States and employs 11,800 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with current market capitalization of 94.84 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Gilead Sciences's market, we take the total number of its shares issued and multiply it by Gilead Sciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Gilead Sciences conducts business under Healthcare sector and is part of Drug Manufacturers?General industry. The entity has 1.25 B outstanding shares of which 25.22 M shares are currently shorted by private and institutional investors with about 2.04 trading days to cover. Gilead Sciences currently holds about 21.02 B in cash with 9 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.76.
Check Gilead Sciences Probability Of Bankruptcy

Ownership Allocation (%)

Gilead Stock Price Odds Analysis

Odds Down 77.19HorizonTargetOdds Up 77.19
57.78%30 days
 77.19 
41.90%
Based on a normal probability distribution, the odds of Gilead Sciences to move above the current price in 30 days from now is about 41.9 (This Gilead Sciences probability density function shows the probability of Gilead Sciences Stock to fall within a particular range of prices over 30 days) .

Gilead Sciences Income Statement Over Time

Gilead Sciences Income Statement is one of the three primary financial statements used for reporting Gilead's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Gilead Sciences revenue and expense. Gilead Sciences Income Statement primarily focuses on the company's revenues and expenses during a particular period. Gilead Sciences Earning Before Interest and Taxes EBIT is projected to increase significantly based on the last few years of reporting. The past year's Earning Before Interest and Taxes EBIT was at 6.18 Billion. The current year Gross Profit is expected to grow to about 18.1 B, whereas Cost of Revenue is forecasted to decline to about 4.4 B. View More Fundamentals

Gilead Stock Against Markets

Did you try this?

Run Efficient Frontier Now

   

Efficient Frontier

Plot and analyze your portfolio and positions against risk-return landscape of the market.
All  Next Launch Module

Gilead Sciences Upcoming and Recent Events

Gilead Sciences Company Earnings Announcements Dates

Upcoming Quarterly Report4th of August 2020
Next Earnings Report22nd of October 2020
Next Fiscal Quarter End30th of June 2020
Next Fiscal Year End2nd of February 2021
Last Quarter Report31st of March 2020
Last Earning Announcement30th of June 2019

Gilead Sciences Corporate Filings

Gilead Sciences SEC Reporting

Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
Submission of Matters to a Vote of Security Holders
View
Unclassified Corporate Event
View

Gilead Sciences Distributions to stockholders

A dividend is the distribution of a portion of Gilead Sciences earnings, decided and managed by the Gilead Sciencess board of directors and paid to a class of its shareholders. Note, announcements of dividend payouts are generally accompanied by a proportional increase or decrease in a company's stock price. Gilead Sciences dividend payments follow a chronological order of events, and the associated dates are important to determine the shareholders who qualify for receiving the dividend payment.
11th of June 2020
12th of March 2020
12th of December 2019
12th of September 2019
13th of June 2019
14th of March 2019
13th of December 2018
13th of September 2018

Gilead Sciences Corporate Directors

Gayle Wilson Independent Director
Jacqueline Barton Director
John Madigan Independent Director
Please check Risk vs Return Analysis. Please also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page